002422 科伦药业
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入13,276,730-20.92%21,812,41421,453,92919,038,21617,277,408
减:营业总成本11,864,487-11.56%17,850,87418,277,36317,223,48416,290,481
    其中:营业成本6,918,963-13.22%10,536,82110,205,5359,040,1587,660,152
               财务费用46,401-14.87%66,179233,761479,834505,647
               资产减值损失(66,882)119.29%(130,590)(130,551)(44,113)(50,428)
公允价值变动收益21,41956.61%19,89814,6669,8614,828
投资收益177,597-38.39%345,018358,882234,580214,829
    其中:对联营企业和合营企业的投资收益158,955-41.81%320,466352,105228,194127,303
营业利润1,779,909-53.28%4,426,3213,654,1432,195,1421,319,843
利润总额1,648,930-55.50%4,285,3593,580,4262,067,9191,177,616
减:所得税费用404,160-48.49%923,404933,787363,697309,499
净利润1,244,771-57.39%3,361,9542,646,6391,704,221868,117
减:非控股权益44,105-90.20%426,062190,527(1,103)(234,438)
股东净利润1,200,666-51.41%2,935,8922,456,1121,705,3241,102,554

市场价值指针
每股收益 (元) *0.750-52.23%1.8601.6901.2200.780
每股派息 (元) *0.126-51.54%0.7630.8000.6160.426
每股净资产 (元) *14.8355.34%14.03713.00910.8649.721
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容